Pulmonary & Respiratory Medicine

Hanneke Eyns

Publications

• Research Article
  Bronchial Hyperreactivity Related to Inhalation Therapy in Cystic Fibrosis Patients
  Author(s): Hanneke Eyns, Julie Willekens, Iris De Schutter, Elke De Wachter, Peter Vaes and Anne MalfrootHanneke Eyns, Julie Willekens, Iris De Schutter, Elke De Wachter, Peter Vaes and Anne Malfroot
  
  It is presumed that bronchial hyperreactivity (BHR) can occur with any inhaled agent and may be a reason for discontinuation of inhalation therapy in cystic fibrosis (CF) patients. On the other hand, inhalation of antibiotics is being increasingly used to eradicate or treat infections. This review focuses on identifying the mechanisms of BHR for a better understanding of its impact on inhalation treatment. BHR in CF is suggested to be secondary to underlying airway disease (associated to poor pulmonary function, chronic inflammation and aerosol distribution) or to be a separate condition occurring more in CF. Furthermore, certain characteristics of the aerosol solution itself, such as the active molecule, chemical additives and particle size, can cause BHR. Recombinant human DNase (rhDNase), hypertonic saline (HS) and the antibiotics tobramycin, colis.. Read More»
  DOI: 10.4172/2161-105X.1000211

  Abstract PDF